Profile
Oscient Pharmaceuticals Corporation is a commercial-stage pharmaceutical company marketing two FDA-approved products in the United States: ANTARA® (fenofibrate) capsules, a cardiovascular product and FACTIVE® (gemifloxacin mesylate) tablets, a fluoroquinolone antibiotic. ANTARA is indicated for the adjunct treatment of hypercholesterolemia (high blood cholesterol) and hypertriglyceridemia (high triglycerides) in combination with diet. FACTIVE is approved for the treatment of acute bacterial exacerbations of chronic bronchitis and community-acquired pneumonia of mild to moderate severity. Oscient also has a novel, late-stage antibiotic candidate, Ramoplanin, under investigation for the treatment of Clostridium difficile-associated disease (CDAD). More >>
Recent Press Releases
DateTitle 
07/13/09Oscient Pharmaceuticals Files Voluntary Petition for Relief Under Chapter 11 of the United States Bankruptcy CodePrinter Friendly Version
06/11/09Oscient Pharmaceuticals Discontinues Sales Force Promotion for ANTARA and FACTIVEPrinter Friendly Version
05/22/09Oscient Pharmaceuticals Receives NASDAQ Letter Regarding Delay in Filing Form 10-QPrinter Friendly Version
Upcoming Events
There are currently no events scheduled.
Featured Reports
Download Documentation 2007 Annual Report
Stock Quote
OSCI (Common Stock)
ExchangeOTHER OTC
Price0.02
Change (%)0.00 (0.00%)
Volume258,584
Data as of 02/08/10 3:32 p.m. ET
Minimum 20 minute delay
Refresh quote
Receive E-mail AlertsE-mail Alert Icon
Alerts are e-mailed to you whenever certain new company information is posted to this site.
Sign-up Now!